Complex Molecular Etiology and Cellular Landscape of Hip Osteoarthritis
NCT ID: NCT05278520
Last Updated: 2025-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
110 participants
OBSERVATIONAL
2023-01-11
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis
NCT03067870
Cellular and Molecular Analysis of Synovial Tissue of Patients With Arthritis
NCT06737952
Osteoarthritis and Body Composition: Evaluation of Systematic Mediators
NCT00771082
Etude 3000 ARTHROSES Symptomatic Knee and Hip Osteoarthritis Prevalence Survey
NCT01400529
Rheumatoid Arthritis and Myositis Cohort
NCT05627089
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Using the latest single-cell RNA sequencing (scRNAseq) techniques the investigators aim to A) characterize what kind of cell populations are found in different synovial tissues and blood derived samples of OA patients, B) determine how the cell composition differs between arthritic and corresponding non-arthritic tissues, C) map the transcriptional and regulatory landscape of the cells mentioned in A and B focusing on the inflammatory responses, D) determine what are the key molecular pathways activated in OA.
2. To determine if some of the blood-derived immune cell populations or their products could be used as biomarkers for OA.
3. To map the whole transcriptome and proteome of OA and non-arthritic control tissue while keeping the morphological context with spatial omics technologies.
4. Further differentiation and identification of OA endotypes utilizing the single-cell and spatial omics data.
The project includes a Rheumatoid sub-study where the main objective is to compare arthritic tissue and peripheral blood constituents between OA and rheumatoid arthritis patients to explore the differences in the disease mechanisms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OA cases
Fifty adult patients who have hip osteoarthritis.
Total hip arthroplasty
Hip joint replacement surgery. Elective for RA and OA cases.
RA cases
Forty adult patients who have rheumatoid arthritis in the hip joint.
Total hip arthroplasty
Hip joint replacement surgery. Elective for RA and OA cases.
Non-arthritic controls
Twenty adult patients who go through trauma-based emergency total hip arthroplasty and do not have arthritis.
Total hip arthroplasty
Hip joint replacement surgery. Elective for RA and OA cases.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Total hip arthroplasty
Hip joint replacement surgery. Elective for RA and OA cases.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Controls: Non-arthritis adult patients who are going through a trauma-based emergency total hip arthroplasty.
\----
Adult patients with rheumatoid arthritis in the hip joint and who are going through an elective total hip arthroplasty.
\----
Exclusion Criteria
* Age \< 18 or \> 74
* The OA patients may not have diabetes, rheumatoid arthritis (RA), or metabolic syndrome.
18 Years
74 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Turku University Hospital
OTHER_GOV
Hospital District of Helsinki and Uusimaa
OTHER
University of Turku
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lea Mikkola
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lea Mikkola, PhD
Role: PRINCIPAL_INVESTIGATOR
Turku Bioscience, University of Turku
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PET-centre, University of Turku
Turku, Southwest Finland, Finland
Turku Bioscience, University of Turku
Turku, Southwest Finland, Finland
Turku University Hospital
Turku, Southwest Finland, Finland
Helsinki University Hospital
Espoo, Uusimaa, Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rydgren E, Kotilainen SK, Piipponen M, Lönnberg T, Mikkola L. COMPARISON OF TWO HIGH-RESOLUTION SPATIAL TRANSCRIPTOMICS TECHNOLOGIES TO STUDY SYNOVIAL IMMUNE INFILTRATION IN OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS Osteoarthritis and Cartilage, Volume 33, Issue 6, 2025, page 816. https://doi.org/10.1016/j.joca.2025.03.079
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022OASEQ
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.